

Crescita Therapeutics™ Inc.
(the “Corporation”)

**Annual and Special Meeting of Shareholders
of the Corporation held on June 20, 2017
(the “Meeting”)**

REPORT OF VOTING RESULTS

*Pursuant to National Instrument 51-102 Continuous Disclosure Obligations
Section 11.3*

Reference should be made to the Corporation’s management information circular dated May 17, 2017 (the “**Information Circular**”) for a full description of the matters voted upon at the Meeting, a copy of which is available at www.sedar.com.

Management Proposals			
Brief Description of Matters Voted Upon	Outcome of the Vote	Percentage of Votes Cast (where the vote was conducted by ballot)	
		For	Withheld
Election of Directors of the Corporation	Approved by ballot		
Daniel N. Chicoine		95.71	4.29
David A. Copeland		96.15	3.85
Anthony E. Dobranowski		96.36	3.64
John C. London		95.72	4.28
Samira Sakhia		96.79	3.21
Thomas Schlader		96.60	3.40
Appointment of Auditors of the Corporation	Approved by ballot	95.90	4.10
		For	Against
Resolution authorizing the issuance of up to 713,214 common shares of the Corporation (each, a “Common Share”) in satisfaction of the balance of the base purchase price owing pursuant to Section 2.3 of the securities purchase agreement dated September 1, 2016 (the “Purchase Agreement”) pursuant to which the Corporation acquired INTEGA Skin Sciences Inc., all as more particularly described in the Information Circular,	Approved by ballot	95.17	4.83

Resolution authorizing the Corporation to issue such number of common shares as is required in satisfaction of any milestone payments that becomes due pursuant to Section 2.8 of the Purchase Agreement, all as more particularly described in the Information Circular.	Approved by ballot	94.98	5.02
---	-----------------------	-------	------